|
| 36773960 | Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs. | J Control Release | 2023 |
| 35335898 | Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2. | Pharmaceutics | 2022 |
| 35740315 | Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. | Biomedicines | 2022 |
| 35476434 | Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis. | Sci Adv | 2022 |
| 36362226 | Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with <sup>99m</sup>Tc for Radionuclide Imaging of HER2 Expression in Cancer. | Int J Mol Sci | 2022 |
| 35890370 | Preclinical Evaluation of a New Format of <sup>68</sup>Ga- and <sup>111</sup>In-Labeled Affibody Molecule Z<sub>IGF-1R:4551</sub> for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. | Pharmaceutics | 2022 |
| 36015242 | Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart. | Pharmaceutics | 2022 |
| 34298801 | Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1. | Cancers (Basel) | 2021 |
| 33806887 | Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. | Pharmaceutics | 2021 |
| 34439094 | Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. | Cancers (Basel) | 2021 |
| 34834262 | Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. | Pharmaceutics | 2021 |
| 32344762 | HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. | Pharmaceutics | 2020 |
| 31863835 | Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. | Int J Biol Macromol | 2020 |
| 33396753 | Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. | Cancers (Basel) | 2020 |
| 31063493 | An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation. | PLoS One | 2019 |
| 31416167 | Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. | Cancers (Basel) | 2019 |
| 31180549 | Potent and specific fusion toxins consisting of a HER2⿿binding, ABD⿿derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A. | Int J Oncol | 2019 |
| 29572538 | In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor. | Sci Rep | 2018 |
| 30172673 | Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. | J Control Release | 2018 |
| 28514998 | Affibody Molecules in Biotechnological and Medical Applications. | Trends Biotechnol | 2017 |
| 27439689 | Fusion of the mouse IgG1 Fc domain to the VHH fragment (ARP1) enhances protection in a mouse model of rotavirus. | Sci Rep | 2016 |
| 27788487 | Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme. | Oncotarget | 2016 |
| 27573289 | Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin. | Int J Oncol | 2016 |
| 25425114 | Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. | Amino Acids | 2015 |
| 26046132 | Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain. | Int J Oncol | 2015 |
| 25406323 | An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein. | Proc Natl Acad Sci U S A | 2014 |
| 26267111 | Inhibitory effects of H-Ras/Raf-1-binding affibody molecules on synovial cell function. | AMB Express | 2014 |
| 23179942 | [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. | Eur J Nucl Med Mol Imaging | 2013 |
| 24260574 | Robust expression of the human neonatal Fc receptor in a truncated soluble form and as a full-length membrane-bound protein in fusion with eGFP. | PLoS One | 2013 |
| 23692562 | HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules. | J Med Chem | 2013 |
| 23752197 | S100A4 interacts with p53 in the nucleus and promotes p53 degradation. | Oncogene | 2013 |
| 22173843 | Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551. | J Nucl Med | 2012 |
| 22249974 | Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. | Tumour Biol | 2012 |
| 21605562 | Novel antigen design for the generation of antibodies to G-protein-coupled receptors. | J Immunol Methods | 2011 |
| 21524142 | Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I. | J Med Chem | 2011 |
| 20088825 | Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. | Biotechnol Appl Biochem | 2010 |
| 20964447 | HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [â¹â¹(m)Tc(CO)â¿¿](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. | Bioconjug Chem | 2010 |
| 20674812 | Selection and characterisation of affibody molecules inhibiting the interaction between Ras and Raf in vitro. | N Biotechnol | 2010 |
| 18260830 | Selection and characterization of Affibody ligands to the transcription factor c-Jun. | Biotechnol Appl Biochem | 2009 |
| 19552886 | Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domain. | N Biotechnol | 2009 |
| 18671978 | Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule. | J Immunol Methods | 2008 |
| 17196217 | Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. | J Immunol Methods | 2007 |
| 17289078 | Evolution of programmable zinc finger-recombinases with activity in human cells. | J Mol Biol | 2007 |
| 17383674 | A novel method for reproducible fluorescent labeling of small amounts of antibodies on solid phase. | J Immunol Methods | 2007 |
| 16892247 | Single-step recovery and solid-phase refolding of inclusion body proteins using a polycationic purification tag. | Biotechnol J | 2006 |
| 15537646 | Exploring strategies for the design of artificial transcription factors: targeting sites proximal to known regulatory regions for the induction of gamma-globin expression and the treatment of sickle cell disease. | J Biol Chem | 2005 |
| 15048831 | Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach. | Proteins | 2004 |
| 15579490 | Negatively charged purification tags for selective anion-exchange recovery. | Protein Eng Des Sel | 2004 |
| 14983098 | Evaluation of different linker regions for multimerization and coupling chemistry for immobilization of a proteinaceous affinity ligand. | Protein Eng | 2003 |
| 11822381 | Strategy for highly selective ion-exchange capture using a charge-polarizing fusion partner. | J Chromatogr A | 2002 |